These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32376304)

  • 21. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.
    Robin J; Weinberg K; Tiongson J; Carnethon M; Reddy M; Ciaccio C; Quadrini M; Hsu J; Fan J; Choi P; Kadish A; Goldberger J; Passman R
    Heart Rhythm; 2006 Oct; 3(10):1196-201. PubMed ID: 17018351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients.
    Bhavnani SP; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Ann Noninvasive Electrocardiol; 2013 Jul; 18(4):379-88. PubMed ID: 23879278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and cardiovascular mortality in implantable cardioverter-defibrillator patients.
    Zhou Y; Zhao S; Chen K; Hua W; Zhang S
    BMC Cardiovasc Disord; 2019 May; 19(1):129. PubMed ID: 31146684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies.
    Kuschyk J; Müller-Leisse J; Duncker D; Tülümen E; Fastenrath F; Fastner C; Kruska M; Akin I; Liebe V; Borggrefe M; Veltmann C; Rudic B
    Int J Cardiol; 2021 Jan; 323():100-105. PubMed ID: 32871189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Myocardial Bridge on Life-Threatening Ventricular Arrhythmia in Patients With Implantable Cardioverter Defibrillator.
    Okada K; Hibi K; Ogino Y; Maejima N; Kikuchi S; Kirigaya H; Kirigaya J; Sato R; Nakahashi H; Minamimoto Y; Kimura Y; Akiyama E; Matsuzawa Y; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
    J Am Heart Assoc; 2020 Nov; 9(21):e017455. PubMed ID: 33094668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).
    Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N
    Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single chamber implantable cardioverter defibrillator compared to dual chamber implantable cardioverter defibrillator: less is more! Data from the German Device Registry.
    Bogossian H; Frommeyer G; Hochadel M; Ince H; Spitzer SG; Eckardt L; Maier SKG; Kleemann T; Brachmann J; Stellbrink C; Gonska BD; Kääb S; Senges J; Lemke B
    Clin Res Cardiol; 2020 Jul; 109(7):911-917. PubMed ID: 31823040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
    Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
    Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator.
    Honarbakhsh S; Providencia R; Srinivasan N; Ahsan S; Lowe M; Rowland E; Hunter RJ; Finlay M; Segal O; Earley MJ; Chow A; Schilling RJ; Lambiase PD
    Int J Cardiol; 2017 Feb; 228():280-285. PubMed ID: 27865198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The subcutaneous implantable cardioverter-defibrillator: A tertiary center experience.
    Khazen C; Magnusson P; Flandorfer J; Schukro C
    Cardiol J; 2019; 26(5):543-549. PubMed ID: 29718532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry.
    Konstantino Y; Haim M; Boxer J; Goldenberg I; Feldman A; Michowitz Y; Glikson M; Suleiman M;
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):718-23. PubMed ID: 26852908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences Between Access to Follow-Up Care and Inappropriate Shocks Based on Insurance Status of Implantable Cardioverter Defibrillator Recipients.
    Sager SJ; Healy C; Ramireddy A; Rivner H; Viles Gonzalez JF; Coffey JO; Rossin N; Lo KM; Goldberger JJ; Myerburg RJ; Mitrani RD
    Am J Cardiol; 2017 Feb; 119(4):594-598. PubMed ID: 27956005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Decision Tree-Based Survival Analysis of Patients with a History of Inappropriate Implantable Cardioverter-Defibrillator Therapy.
    Yamamoto M; Okajima K; Shimane A; Ozawa T; Morishima I; Asai T; Takagi M; Kasai A; Fujii E; Kiyono K; Watanabe E; Ozaki Y
    Int Heart J; 2019 Mar; 60(2):318-326. PubMed ID: 30745538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.